Maher Elhassan

Tell us about your organisation and its journey to date.

Since its establishment in 1897, BD has become one of the global leaders in the medical technology industry, impacting billions of patients around the world. Throughout our 125-year history as one of the largest global medical technology companies, we have used our capabilities, expertise and scale to address critical healthcare needs for people around the world. 

Time and time again, BD has stepped up to make a difference by innovating faster to deliver critical products and solutions that save lives. We have done this to help patients no matter where they are in their healthcare journey — getting routine checks or battling chronic illness — on a large, global scale to combat some of the world’s biggest health crises like polio, HIV and the recent pandemic. The company produces over 45 billion devices, servicing more than 190 countries, and works closely with over 77,000 associates across the globe. 

Today, we build upon our commitment to advancing the world of healthTM in every aspect of the organisation’s operations through meaningful actions impacting the industry. We are dedicated to strengthening healthcare systems across the MENAT region by developing and deploying market-appropriate solutions operating through our network of distributors and BD offices boasting a team of over 400 associates in the UAE, Saudi Arabia, Turkey and Egypt. 

Our priority at BD is to ensure that our medical technologies are of the highest quality to empower the healthcare industry to build resilience against future health challenges.  

Give us an insight into your portfolio and solutions targeted at the Middle East region.

At BD, we prioritise providing offering optimised tools and solutions that increase financial sustainability and efficiency across healthcare organisations, improving safety to protect patients and caregivers and expanding access to quality care, to providing healthcare professionals with personalised and timely supports all along the patient journey. Maintaining quality throughout the patient care journey is of utmost importance for the organisation, and we continue to enhance the care experience with an integrated, holistic approach.  

As one of the world’s largest MedTech organisations, BD has continued to innovate through its Life Sciences, Medical and Interventional segments globally and in the region. Customers interested in our Life Sciences segment can visit us during Medlab 2023 to learn more about our innovations in Integrated Diagnostic Solutions and Biosciences. 

What will you be showcasing at Medlab Middle East 2023? 

This year at Medlab 2023, BD’s Life Sciences segment will showcase our commitment to sustainable healthcare through a focus on patient safety, healthcare workers, and efficiency solutions that are designed to help healthcare institutions minimise waste and inefficiencies to unlock their hidden capacities and drive financial sustainability.  

As part of our integrated diagnostic solutions customers can discover our latest innovations in laboratory diagnosis combined with workflow optimisation and digital solutions. They can also learn about our latest innovations in biosciences that help in research discoveries. 

To compliment its showcase, BD will also be hosting multiple insightful training sessions on our integrated diagnostic solutions in addition to a biosciences workshop on February 6 on Cytognos joining BD and Infinicyt.  

In addition to the above, what opportunities are you looking forward to at the upcoming event?

As briefly touched upon, each year we return up to 25 per cent of our turnover into R&D, and around one-quarter of our staff are research scientists and engineers. One key focus for Randox is to improve therapeutic intervention through novel testing panel utilising the capabilities of our patented Biochip Technology.

Clinical panel development is well underway for the Evidence MultiSTAT which includes the Stoke array to complement and enhance CT scanning technology to facilities accurate classification of stroke patients within 30 minutes. ARDS is another panel for the stratification of hypo and hyper-inflammatory subphenotypes in ARDS patients within 36 minutes and from the COVID pandemic Randox has focused investment into detecting key markers implicated in cytokine toxicity in patients with an acute hyper-inflammatory response in 60 minutes.

What will you be showcasing at Medlab Middle East 2023? 

Platforms like Medlab Middle East allow us to further strengthen BD’s purpose of advancing the world of healthTM, motivating us to collaborate and work closely with industry professionals to help secure the future of healthcare.

 We look forward to discussing the advancements of smart connected care, where AI, informatics, and robotics have the capabilities of significantly transforming healthcare processes, tools, and treatments.  

We are committed to transforming healthcare to become more sustainable by offering optimised tools and solutions that increase financial sustainability and efficiency across healthcare organisations, improving safety to protect patients and caregivers and expanding access to quality care, to providing healthcare professionals with personalised and timely support all along the patient journey. 

 Our 125 years of experience has enabled strategic partnerships and a broad manufacturing and distribution scale that positions us as key actors in providing the right care, at the right place, at the right time.  

We look forward to taking this forward with local stakeholders at the show aiming to raise more awareness on the critical role of medical technology in enhancing patient safety, quality of care and care delivery, and how our solutions can help minimise waste and inefficiencies to unlock their hidden capacities and drive financial sustainability.